|From: singhtelecom (Rep: 959)||Date: 02/12/2018 07:43|
|Forum: Nabriva Therapeutics AG - Msg #26||Thread #673990531 (Rec: 0) |
| VENBIO incresed 800% from 220k to 2 MILLION 1.announces that it has completed enrollment in its second lefamulin evaluation against pneumonia (LEAP 2) Phase 3 clinical trial. LEAP 2, which is designed to assess the efficacy and safety of oral lefamulin compared to oral moxifloxacin in adult patients with moderate community-acquired bacterial pneumonia (CABP), completed enrollment of 738 patients. The company anticipates topline clinical results from LEAP 2 to be available in the spring of 2018.|
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.